Notably, we used the PD-L1 clone 73-10, which has not been approved for BC but has been used in the assessment of lung cancer and is comparable to the Dako/Agilent 22C3 assay [13], an approved companion diagnostic for pembrolizumab in the treatment of TNBC. This evidence concerns the gene CD274 and lung cancer.